Ghana targets first locally made tetanus-diphtheria vaccine by early 2027
The first of three bulk substances needed for production has arrived, while Cabinet approval is being sought for 10-year procurement agreements.
Ghana expects to begin making its first locally manufactured vaccine, a tetanus-diphtheria shot, by the first quarter of 2027, National Vaccine Institute chief executive Sodzi Sodzi-Tettey said. The first of three bulk substances needed for production has arrived from Indonesia and is at Atlantic Life Sciences.
Sodzi-Tettey said the substance was supplied under a grant arrangement negotiated by the Health Ministry and received a tax exemption. The government has fully funded equipment, installation and training for a new mRNA laboratory. Ghana’s recently approved pharmaceutical manufacturing policy also provides incentives for local production, he said.
A Cabinet memorandum seeking approval for advance market commitments and 10-year procurement agreements has been finalised by the health minister. Sodzi-Tettey estimated Ghana would need at least US$50 million a year for vaccine purchases after external support arrangements end. The institute plans to establish a biomanufacturing training consortium by the end of 2027.
Why it mattersThe government must decide whether to direct part of its annual vaccine procurement spending, estimated at at least US$50 million, to local production.